Tumor necrosis as a key refinement of risk stratification in gastric gastrointestinal stromal tumors

Chang et al. report a large multicenter retrospective study titled “Tumor necrosis, an independent prognostic factor for predicting gastric gastrointestinal stromal tumors” (1). In this study, the authors analyzed 1,463 patients with gastric gastrointestinal stromal tumors (GISTs) who underwent radical resection and were followed longitudinally for overall survival. Given the relative rarity of GIST and the heterogeneity of its clinical course, the availability of such a large, well-characterized cohort represents an important contribution to the field.

Accurate risk stratification remains central to the management of GIST, particularly for determining postoperative surveillance intensity and the indication and duration of adjuvant imatinib therapy. Although current classification systems based on tumor size, mitotic count, and location are widely used (2-5), substantial prognostic variability persists within individual risk categories, especially among high-risk patients. Chang et al. address a clinically relevant question by examining whether tumor necrosis, a routinely assessable histopathological feature, can improve prognostic discrimination beyond existing models.

A major strength of this study is its large scale and methodological rigor. Tumor necrosis was identified in 16.3% of cases and was significantly associated with tumor size, mitotic count, and modified National Institutes of Health (NIH) category. Importantly, multivariable analysis demonstrated that necrosis was an independent predictor of overall survival, alongside tumor size and mitotic activity. Most notably, the adverse prognostic impact of necrosis was confined to the high-risk group, in which the 5-year survival rate decreased substantially in necrosis-positive tumors. By further stratifying high-risk patients into high- and very-high-risk categories, the authors propose a five-tier system that demonstrates superior prognostic discrimination compared with the conventional four-tier modified NIH classification.

This approach is conceptually appealing. Rather than replacing established systems, the authors refine them, consistent with recent efforts in other oncologic fields where incremental biomarkers enhance rather than supplant classical staging frameworks. The simplicity of a binary necrosis assessment, defined as present or absent, also favors its clinical applicability. Pathologists can incorporate this parameter into routine reports without additional cost or specialized assays, potentially allowing immediate translation into practice.

In addition to its prognostication, its clinical implications are substantial. Current guidelines recommend 3 years of adjuvant imatinib for high-risk GIST (6,7); however, a subset of patients relapse early despite standard therapy. Chang et al. provide evidence that necrosis identifies a particularly poor prognosis subgroup that may benefit from intensified or prolonged adjuvant strategies. Their findings therefore align directly with the evolving paradigm of treatment personalization in GIST.

The biological plausibility of these observations further strengthens the findings of this study. Tumor necrosis is characterized by hypoxia, metabolic stress, and rapid proliferation, which promote genomic instability, clonal selection, and treatment resistance. Necrosis is also associated with hypoxia-inducible factor signaling, pro-inflammatory microenvironmental changes, and aggressive tumor behavior. In this context, necrosis should be viewed not merely as a passive bystander, but as a surrogate marker of hostile tumor biology.

Several issues warrant further investigation. First, necrosis was histologically assessed after resection, and its preoperative identification remains challenging. Advances in radiomics and functional imaging may eventually enable noninvasive prediction of necrosis, allowing risk refinement before surgery (8). Second, molecular features such as KIT and PDGFRA mutations were not incorporated into the proposed model. Future integrated approaches that combine histopathological, genomic, and imaging biomarkers may yield greater prognostic precision. Third, although overall survival is a robust endpoint, analyses of disease-free survival and recurrence patterns may provide additional insight into the influence of necrosis on the natural history of GIST.

The authors’ work also raises broader questions for the field. How far should we push risk stratification complexity before clinical usability is compromised? The proposed five-tier system remains intuitive; however, each added variable increases interpretive burden. Balancing precision and simplicity will be critical as future models continue to evolve.

In summary, Chang et al. provide compelling evidence that tumor necrosis is a clinically meaningful biomarker in gastric GIST. By refining the modified NIH classification, they offer a practical step toward more accurate prognostication and individualized adjuvant therapy. Their study exemplifies how careful reassessment of routinely available pathological features can meaningfully advance precision oncology. We thank the authors for this important contribution and anticipate that their findings will stimulate further prospective validation and integration into future guidelines.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article did not undergo external peer review.

Funding: None.

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2026-1-0108/coif). The author has no conflicts of interest to declare.

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Chang K, Li R, Zhang P, et al. Tumor necrosis, an independent prognostic factor for predicting gastric gastrointestinal stromal tumors. J Gastrointest Oncol 2025;16:1393-402. [Crossref] [PubMed]
2. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65. [Crossref] [PubMed]
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83. [Crossref] [PubMed]
4. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. [Crossref] [PubMed]
5. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39:1411-9. [Crossref] [PubMed]
6. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol 2016;34:244-50. [Crossref] [PubMed]
7. Joensuu H. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management. Drugs 2012;72:1953-63. [Crossref] [PubMed]
8. Chu H, Pang P, He J, et al. Value of radiomics model based on enhanced computed tomography in risk grade prediction of gastrointestinal stromal tumors. Sci Rep 2021;11:12009. [Crossref] [PubMed]